Free Trial

Atyr PHARMA (ATYR) News Today

Atyr PHARMA logo
$3.16 -0.07 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$3.20 +0.04 (+1.39%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATYR Latest News

Atyr PHARMA INC stock logo
Wells Fargo & Company MN Invests $383,000 in Atyr PHARMA INC (NASDAQ:ATYR)
Wells Fargo & Company MN purchased a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 105,769 shares of the company's stock, valued at a
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from Brokerages
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to th
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 20.6% in April
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 10,030,000 shares, an increase of 20.6% from the March 31st total of 8,320,000 shares. Approximately 11.7% of the company's stock are sold short. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is currently 7.2 days.
Atyr PHARMA INC stock logo
FY2026 EPS Estimates for Atyr PHARMA Decreased by Analyst
Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Atyr PHARMA in a report issued on Tuesday, April 29th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per sha
Atyr PHARMA INC stock logo
Ally Bridge Group NY LLC Invests $2.53 Million in Atyr PHARMA INC (NASDAQ:ATYR)
Ally Bridge Group NY LLC acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 699,730 shares of the company's stock, valued at approximately $2,533,000. Atyr PHARMA mak
Atyr PHARMA INC stock logo
248,000 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Acquired by 683 Capital Management LLC
683 Capital Management LLC bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 248,000 shares of the company's stock, valued at
Atyr PHARMA FY2026 EPS Forecast Reduced by HC Wainwright
Atyr PHARMA INC stock logo
Adage Capital Partners GP L.L.C. Buys New Shares in Atyr PHARMA INC (NASDAQ:ATYR)
Adage Capital Partners GP L.L.C. purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,000,000 shares of the company's stock, v
Atyr PHARMA INC stock logo
JPMorgan Chase & Co. Boosts Stake in Atyr PHARMA INC (NASDAQ:ATYR)
JPMorgan Chase & Co. raised its position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) by 467.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,532 shares of the company's stock after bu
Atyr PHARMA INC stock logo
Atyr PHARMA (ATYR) Projected to Post Earnings on Thursday
Atyr PHARMA (NASDAQ:ATYR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-atyr-pharma-inc-stock-1/)
Atyr PHARMA INC stock logo
Geode Capital Management LLC Buys Shares of 891,407 Atyr PHARMA INC (NASDAQ:ATYR)
Geode Capital Management LLC bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 891,407 shares of the company's
Atyr PHARMA INC stock logo
Renaissance Technologies LLC Makes New $2.08 Million Investment in Atyr PHARMA INC (NASDAQ:ATYR)
Renaissance Technologies LLC acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 574,455 shares of the company's stock, valued at a
Atyr PHARMA INC stock logo
Atyr PHARMA (ATYR) to Release Quarterly Earnings on Thursday
Atyr PHARMA (NASDAQ:ATYR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-atyr-pharma-inc-stock-1/)
Piper Sandler Reaffirms Their Buy Rating on aTyr Pharma (ATYR)
Atyr PHARMA INC stock logo
American Century Companies Inc. Makes New $319,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR)
American Century Companies Inc. acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 88,112 shares of the company's stock, valued at approximately $319,000
Atyr PHARMA INC stock logo
14,666,600 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Acquired by Federated Hermes Inc.
Federated Hermes Inc. acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 14,666,600 shares of the company's stock, valued at approximately
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Given Consensus Rating of "Buy" by Brokerages
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation
Atyr PHARMA INC stock logo
Tikvah Management LLC Acquires Shares of 2,460,833 Atyr PHARMA INC (NASDAQ:ATYR)
Tikvah Management LLC acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,460,833 shares of the company's stock, valued at
Atyr PHARMA INC stock logo
Knott David M Jr Purchases Shares of 308,133 Atyr PHARMA INC (NASDAQ:ATYR)
Knott David M Jr acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 308,133 shares of the company's stock, valued at
Atyr PHARMA INC stock logo
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 31.6%
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 6,920,000 shares, a growth of 31.6% from the February 28th total of 5,260,000 shares. Currently, 8.1% of the company's stock are short sold. Based on an average daily trading volume, of 1,260,000 shares, the short-interest ratio is currently 5.5 days.
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 5,260,000 shares, a growth of 20.9% from the February 13th total of 4,350,000 shares. Approximately 6.5% of the shares of the stock are short sold. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 4.6 days.
Atyr PHARMA INC stock logo
Jane A. Gross Purchases 3,750 Shares of Atyr PHARMA INC (NASDAQ:ATYR) Stock
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) Director Jane A. Gross acquired 3,750 shares of Atyr PHARMA stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $4.00 per share, with a total value of $15,000.00. Following the acquisition, the director now directly owns 9,750 shares of the company's stock, valued at approximately $39,000. This trade represents a 62.50 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Atyr PHARMA INC stock logo
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR)
HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Friday.
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Brokerages
Shares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on
Atyr PHARMA INC stock logo
Atyr PHARMA (NASDAQ:ATYR) Issues Earnings Results
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05.
Atyr PHARMA INC stock logo
Atyr PHARMA (NASDAQ:ATYR) Announces Quarterly Earnings Results
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05.
aTyr Pharma (ATYR) Gets a Buy from Piper Sandler
aTyr Pharma shares fall as Q4 loss narrows
aTyr Pharma reports Q4 EPS (18c), consensus (23c)
Piper Sandler Remains a Buy on aTyr Pharma (ATYR)
Get Atyr PHARMA News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.

ATYR Media Mentions By Week

ATYR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATYR
News Sentiment

0.74

0.64

Average
Medical
News Sentiment

ATYR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATYR Articles
This Week

15

2

ATYR Articles
Average Week

Get Atyr PHARMA News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ATYR) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners